Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V Sinn

Showing results (21-30 of 57) with videos related to

Pageof 6
Sort By:
BMC Cancer|February 5, 2021
Targeted RNAseq assay incorporating unique molecular identifiers for improved quantification of gene expression signatures and transcribed mutation fraction in fixed tumor samplesChunxiao Fu, Michal Marczyk, Michael Samuels, et al.
Virchows Archiv : an International Journal of Pathology|November 14, 2009
Vascular endothelial growth factor C mRNA expression is a prognostic factor in epithelial ovarian cancer as detected by kinetic RT-PCR in formalin-fixed paraffin-embedded tissueBruno V Sinn, Silvia Darb-Esfahani, Ralph M Wirtz, et al.
Pancreas|April 1, 2014
KRAS mutations in codon 12 or 13 are associated with worse prognosis in pancreatic ductal adenocarcinomaBruno V Sinn, Jana K Striefler, Marc A Rudl, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 25, 2014
SPARC expression in resected pancreatic cancer patients treated with gemcitabine: results from the CONKO-001 studyM Sinn, B V Sinn, J K Striefler, et al.
Endocrine-Related Cancer|August 14, 2009
Estrogen receptor 1 mRNA is a prognostic factor in ovarian carcinoma: determination by kinetic PCR in formalin-fixed paraffin-embedded tissueSilvia Darb-Esfahani, Ralph M Wirtz, Bruno V Sinn, et al.
Journal of the American Society of Cytopathology|December 12, 2024
Comparative analysis of Ficoll-Hypaque and CytoLyt techniques for blood removal in breast cancer malignant effusions: effects on RNA quality and sequencing outcomesGloria H Sura, Kevin Tran, Alexander J Trevarton, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 3, 2020
<i>TP53</i> Mutations Predict Sensitivity to Adjuvant Gemcitabine in Patients with Pancreatic Ductal Adenocarcinoma: Next-Generation Sequencing Results from the CONKO-001 TrialMarianne Sinn, Bruno V Sinn, Denise Treue, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 11, 2013
Evaluation of Mucin-1 protein and mRNA expression as prognostic and predictive markers after neoadjuvant chemotherapy for breast cancerB V Sinn, G von Minckwitz, C Denkert, et al.
Breast Cancer Research : BCR|February 9, 2013
HER2 and ESR1 mRNA expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancerCarsten Denkert, Jens Huober, Sibylle Loibl, et al.
Clinical Epigenetics|October 4, 2021
DNA methylation profiling identifies two distinct subgroups in breast cancers with low hormone receptor expression, mainly associated with HER2 amplification statusPhilipp Jurmeister, Karsten Weber, Sonia Villegas, et al.
Pageof 6

Showing results (21-30 of 57) with videos related to

Sort By:
Pageof 6
BMC Cancer|February 5, 2021
Targeted RNAseq assay incorporating unique molecular identifiers for improved quantification of gene expression signatures and transcribed mutation fraction in fixed tumor samplesChunxiao Fu, Michal Marczyk, Michael Samuels, et al.
Virchows Archiv : an International Journal of Pathology|November 14, 2009
Vascular endothelial growth factor C mRNA expression is a prognostic factor in epithelial ovarian cancer as detected by kinetic RT-PCR in formalin-fixed paraffin-embedded tissueBruno V Sinn, Silvia Darb-Esfahani, Ralph M Wirtz, et al.
Pancreas|April 1, 2014
KRAS mutations in codon 12 or 13 are associated with worse prognosis in pancreatic ductal adenocarcinomaBruno V Sinn, Jana K Striefler, Marc A Rudl, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 25, 2014
SPARC expression in resected pancreatic cancer patients treated with gemcitabine: results from the CONKO-001 studyM Sinn, B V Sinn, J K Striefler, et al.
Endocrine-Related Cancer|August 14, 2009
Estrogen receptor 1 mRNA is a prognostic factor in ovarian carcinoma: determination by kinetic PCR in formalin-fixed paraffin-embedded tissueSilvia Darb-Esfahani, Ralph M Wirtz, Bruno V Sinn, et al.
Journal of the American Society of Cytopathology|December 12, 2024
Comparative analysis of Ficoll-Hypaque and CytoLyt techniques for blood removal in breast cancer malignant effusions: effects on RNA quality and sequencing outcomesGloria H Sura, Kevin Tran, Alexander J Trevarton, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 3, 2020
<i>TP53</i> Mutations Predict Sensitivity to Adjuvant Gemcitabine in Patients with Pancreatic Ductal Adenocarcinoma: Next-Generation Sequencing Results from the CONKO-001 TrialMarianne Sinn, Bruno V Sinn, Denise Treue, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 11, 2013
Evaluation of Mucin-1 protein and mRNA expression as prognostic and predictive markers after neoadjuvant chemotherapy for breast cancerB V Sinn, G von Minckwitz, C Denkert, et al.
Breast Cancer Research : BCR|February 9, 2013
HER2 and ESR1 mRNA expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancerCarsten Denkert, Jens Huober, Sibylle Loibl, et al.
Clinical Epigenetics|October 4, 2021
DNA methylation profiling identifies two distinct subgroups in breast cancers with low hormone receptor expression, mainly associated with HER2 amplification statusPhilipp Jurmeister, Karsten Weber, Sonia Villegas, et al.
Pageof 6